Breaking AI & Tech News Analyzed

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."

The Sunbed Association's Misleading Claims The body that represents the UK's sunbed salons, the Sunbed Association, has been accused of providing false information on its website, claiming that a tan protects against sunburn. This claim has been disputed by several leading medical bodies, including Cancer Research UK and the British Association of Dermatologists. The Health Risks of Tanning Health organizations have challenged the accuracy of the information being disseminated by the Sunbed Association. The association's website claims that sunburn is "thought to be the main cause of melanoma" and that "if you avoid getting sunburned, the benefits of moderate sun exposure will far outweigh the risks." However, medical experts argue that a tan is a sign of skin damage and offers little protection against the sun. The Data Analysis Melanoma skin cancer is the fifth most common cancer in the UK, with 19,400 new diagnoses and 2,600 deaths every year. The NHS, National Institute for Health and Care Excellence, European Commission, and the US's Centers for Disease Control and Prevention and Food and Drug Administration all highlight the risk of tanning. The Impact Analysis The Sunbed Association's claims have been criticized for being misleading and potentially dangerous. Full Fact, a fact-checking organization, has stated that the association's website "contains incorrect health advice on tanning" and warns that "bad health information can be very dangerous." The Prediction It is likely that the Sunbed Association will face increased scrutiny and criticism from health organizations and fact-checking bodies. The association's claims have been disputed by several leading medical bodies, and it is unlikely that they will be able to justify their position with scientific evidence.

The latest analysis by Cancer Research UK reveals that melanoma, the most serious form of skin cancer, hit a historic high in the United Kingdom last year, with 20,980 diagnoses in 2022. Experts warn that without stronger prevention measures, annual cases could climb to 26,500 by 2040, coinciding with hotter summers and an ageing demographic. Record Melanoma Diagnoses in 2022 For the first time, UK melanoma cases have exceeded the 20,000 mark. The surge reflects broader trends in skin‑cancer incidence and underscores the urgency of public‑health interventions. Projected Growth to 26,500 Cases by 2040 Forecasted annual cases for 2040: 26,500 Increase of 23% among men Increase of 26% among women Drivers: ageing population, higher UV exposure, and lifestyle factors Public Health Implications Amid Heatwave Alerts Heat health alerts have been issued for the upcoming bank‑holiday weekend, with temperatures expected to reach up to 30°C in parts of England. Elevated UV levels amplify the risk of sunburn and, consequently, melanoma development, especially for vulnerable groups. Preventive Strategies and Policy Recommendations Key voices—including Michelle Mitchell, CEO of Cancer Research UK, and Prof Peter Johnson, NHS England’s national clinical director for cancer—stress the importance of: Seeking shade during peak sun hours Wearing protective clothing, hats, and sunglasses Applying broad‑spectrum sunscreen with at least SPF 30 and reapplying regularly Promptly consulting a GP about new or changing moles, sores, or skin patches Outlook for Sun Safety and Cancer Prevention If the public adopts these preventive measures, the rise in melanoma cases could be mitigated despite demographic pressures and hotter summers. Ongoing education, stronger sunscreen regulations, and targeted campaigns during heatwaves are likely to shape the trajectory of skin‑cancer incidence in the UK over the next two decades.